Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response
Chanté L. Richardson, … , Stefano Rivella, Adam N. Goldfarb
Chanté L. Richardson, … , Stefano Rivella, Adam N. Goldfarb
Published July 25, 2013
Citation Information: J Clin Invest. 2013;123(8):3614-3623. https://doi.org/10.1172/JCI68487.
View: Text | PDF
Research Article Hematology Article has an altmetric score of 13

Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response

  • Text
  • PDF
Abstract

The unique sensitivity of early red cell progenitors to iron deprivation, known as the erythroid iron restriction response, serves as a basis for human anemias globally. This response impairs erythropoietin-driven erythropoiesis and underlies erythropoietic repression in iron deficiency anemia. Mechanistically, the erythroid iron restriction response results from inactivation of aconitase enzymes and can be suppressed by providing the aconitase product isocitrate. Recent studies have implicated the erythroid iron restriction response in anemia of chronic disease and inflammation (ACDI), offering new therapeutic avenues for a major clinical problem; however, inflammatory signals may also directly repress erythropoiesis in ACDI. Here, we show that suppression of the erythroid iron restriction response by isocitrate administration corrected anemia and erythropoietic defects in rats with ACDI. In vitro studies demonstrated that erythroid repression by inflammatory signaling is potently modulated by the erythroid iron restriction response in a kinase-dependent pathway involving induction of the erythroid-inhibitory transcription factor PU.1. These results reveal the integration of iron and inflammatory inputs in a therapeutically tractable erythropoietic regulatory circuit.

Authors

Chanté L. Richardson, Lorrie L. Delehanty, Grant C. Bullock, Claudia M. Rival, Kenneth S. Tung, Donald L. Kimpel, Sara Gardenghi, Stefano Rivella, Adam N. Goldfarb

×

Figure 3

Influences of IFN-γ on erythroid aconitase activity and of iron restriction and IC on IFN-γ–mediated signaling.

Options: View larger image (or click on image) Download as PowerPoint
Influences of IFN-γ on erythroid aconitase activity and of iron restrict...
(A) Mitochondrial (M) and cytosolic (C) aconitase activities in human progenitors subjected to IFN-γ treatment ± iron restriction and IC. Gel-based enzymography was performed on extracts of cells cultured 4 days in erythroid medium under the indicated conditions. (B) Time-course analysis of the influence of iron restriction on IFN-γ activation of STAT1. Whole-cell lysates from human progenitors cultured in erythroid medium with IFN-γ ± iron restriction underwent immunoblot (IB) analysis of STAT1 phosphorylation and expression (C–E) Influences of iron restriction and IC on IFN-γ signaling via JAK-STAT. Progenitors cultured 3 days in erythroid medium under the indicated conditions were analyzed as in B. (F) Influences of iron restriction and IC on IFN-γ signaling via the GATE pathway. Cells cultured as in C–E underwent qRT-PCR assessment of IRF9 mRNA levels, with normalization to GAPDH. Results shown as fold increase relative to levels in cells cultured without IFN-γ and with 100% TSAT. All data are mean ± SEM. n = 3.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Referenced in 1 patents
26 readers on Mendeley
See more details